跳至主要内容
临床试验/NCT04034095
NCT04034095已完成不适用

The Registry to Observe Clinical Outcomes of Patients With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Janssen Pharmaceutical K.K.77 个研究点 分布在 1 个国家目标入组 979 人开始时间: 2019年7月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
979
试验地点
77
主要终点
PSA Progression-free Survival (PSA-PFS)

研究概览

简要总结

The purpose of this registry study is to longitudinally observe clinical outcomes and patient-reported outcomes (PRO) for participants with high-risk metastatic hormone-naive prostate cancer (mHNPC) in the real-world setting in Japan.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Documented diagnosis of metastatic, hormone-naïve prostate cancer (mHNPC) after 1 May 2019
  • Should have at least 2 of the 3 following high-risk factors: a Gleason score of greater than or equal to (>=) 8, at least 3-bone lesions, or the presence of visceral metastasis
  • Willing to receive androgen-deprivation therapy (ADT) containing regimens for high-risk metastatic, hormone-naïve prostate cancer (mHNPC) in the hospital which have the contract with sponsor for this study, or patient received a regimen containing ADT for high-risk mHNPC
  • Possess Japanese nationality
  • Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he understands the purpose of, and procedures required for the study and is willing to participate in the study. For dead cases, the ICF can be waived after approved by Independent Ethics Committee/Institutional Review Board (IEC/IRB)

排除标准

  • - has any other active malignancies

研究组 & 干预措施

Cohort 1: ADT alone/ ADT + Bicalutamide

Participants with diagnosis of metastatic hormone-naive prostate cancer (mHNPC) receiving androgen-deprivation therapy (ADT) alone or ADT plus bicalutamide (combined androgen blockade [CAB]) under routine clinical practice will be observed.

干预措施: Androgen-deprivation Therapy (ADT) (Drug)

Cohort 1: ADT alone/ ADT + Bicalutamide

Participants with diagnosis of metastatic hormone-naive prostate cancer (mHNPC) receiving androgen-deprivation therapy (ADT) alone or ADT plus bicalutamide (combined androgen blockade [CAB]) under routine clinical practice will be observed.

干预措施: Bicalutamide (Drug)

Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide

Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.

干预措施: Androgen-deprivation Therapy (ADT) (Drug)

Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide

Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.

干预措施: Abiraterone (Drug)

Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide

Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.

干预措施: Prednisolone (Drug)

Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide

Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.

干预措施: Docetaxel (Drug)

Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide

Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.

干预措施: Enzalutamide (Drug)

Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide

Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.

干预措施: Apalutamide (Drug)

结局指标

主要结局

PSA Progression-free Survival (PSA-PFS)

时间窗: Up to 5 years

The PSA-PFS is defined as the duration from registration to either PSA progression or death, whichever occurs first.

Montreal Cognitive Assessment (MoCA) Score

时间窗: Up to 5 years

The MoCA is a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The total possible score is 30 points; a score of 26 or above is considered normal.

Percentage of Participants who Achieve Prostate-specific Antigen (PSA) <=0.2 ng/mL Within a Year from Registration

时间窗: 1 year

Percentage of participants who achieve prostate-specific antigen (PSA) less than or equal to (\<=)0.2 nanogram per milliliter (ng/mL) within a year from registration will be reported.

Functional Assessment of Cancer Therapy for Prostate Cancer (FACT-P) Questionnaire Score

时间窗: Up to 5 years

The FACT-P consists of the FACT-General (FACT-G) and a PC-specific subscale. The FACT-G (Version 4) contains a 27-item questionnaire and is composed of 4 dimensions of health-related quality of life (HRQoL): physical well-being, social/family well-being, emotional well-being, and functional well-being. The PC-specific subscale is composed of 12 items, which span the dimensions of sexual function, bowel/bladder function, and pain. Each item for FACT-G subscale and PC-specific subscale is rated on a 0 to 4 Likert type scale. Higher scores represent better QoL.

Percentage of Participants with PSA-PFS

时间窗: 2 years

Percentage of participants with PSA-PFS at 2 years from registration will be reported.

Progression-free Survival (PFS)

时间窗: Up to 5 years

The PFS is defined as the duration from registration to either radiographic progression, clinical progression or death, whichever occurs first.

Percentage of Participants with PFS

时间窗: 3 years

Percentage of participants with PFS at 3 years from registration will be reported.

Overall Survival (OS)

时间窗: Up to 5 years

The OS is defined as the duration from registration to any death.

Percentage of Participants with Overall Survival (OS)

时间窗: 3 years

Percentage of participants with OS at 3 years from registration will be reported.

Cancer Specific Survival (CSS)

时间窗: Up to 5 years

The CSS is defined as the duration from registration to prostate cancer (PC)-related death. The PC-related death will be determined by each physician's discretion.

Percentage of Participants with CSS

时间窗: 3 years

Percentage of participants with CSS at 3 years from registration will be reported.

Patient Health Questionnaire-9 (PHQ-9) Score

时间窗: Up to 5 years

The PHQ-9 is a multipurpose self-reported inventory used for screening, diagnosing, and measuring the severity of mental status or depression of the patient. It contains 2 weeks recall of information and scores each of the 9 Diagnostic and Statistical Manual of Mental Disorders (4th edition; DSM-IV) criteria as "0" (not at all) to "3" (nearly every day).

Time to Symptomatic Skeletal Event (TTSSE)

时间窗: Up to 5 years

The TTSSE is defined as the duration from registration to any first symptomatic skeletal event (SSE). The SSE is defined as 1 of the following: symptomatic pathological fracture, spinal cord compression, palliative radiation to bone and surgery to bone.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (77)

Loading locations...

相似试验